Press releases
- Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema
- Ionis to hold donidalorsen Phase 3 data webcast
- New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)
- Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
- Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
- Ionis to host 2024 virtual Annual Meeting of Stockholders
- Ionis reports first quarter 2024 financial results
- Ionis Publishes 2023 Corporate Responsibility Report
- Ionis to hold first quarter 2024 financial results webcast
- Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
More ▼
Key statistics
As of last trade Ionis Pharmaceuticals Inc (0JDI:LSE) traded at 39.16, 7.58% above its 52-week low of 36.40, set on May 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 39.16 |
Average volume | 138.00 |
---|---|
Shares outstanding | 145.97m |
Free float | 144.70m |
P/E (TTM) | -- |
Market cap | 5.82bn USD |
EPS (TTM) | -2.67 USD |
Data delayed at least 20 minutes, as of Jun 07 2024 16:53 BST.
More ▼